| 1. |
- Rubboli, Andrea, et al.
(författare)
-
Esperienza iniziale sulluso di abciximab nel trattamento di salvataggio della trombosi coronarica acuta nel Laboratorio di Emodinamica [Initial experience with the use of abciximab in the salvage treatment of acute coronary thrombosis in the Hemodynamics Laboratory]
- 1998
-
Ingår i: Cardiologia (Rome, Italy). - 0393-1978. ; 43:11, s. 1221-1229
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The optimal treatment of acute thrombotic complications in the Catheterization Laboratory has not been defined yet, due to the limited efficacy shown by various pharmacological regimens, even when associated to coronary angioplasty (PTCA). The aim of our study was therefore to evaluate the effects of abciximab (ReoPro), a new potent inhibitor of the platelet glycoprotein IIb/IIIa, when administered as a rescue treatment for acute thrombotic coronary occlusion during diagnostic or interventional procedures. Sixteen patients (12 males, 4 females, mean age 59.3 +/- 9.2 years, range 43-77 years), with unstable angina and consecutively treated with abciximab due to clinical instability attributable to coronary thrombosis angiographically proven during PTCA (9 cases) or diagnostic angiography (7 cases), were identified. The individual angiographic films and medical records were then reviewed in order to evaluate the effects of treatment on coronary flow, thrombus size and occurrence of in-hospital adverse events: death, non-fatal acute myocardial infarction (AMI), need for urgent myocardial revascularization and hemorrhage. The administration of abciximab, in association with PTCA (associated in turn with stent implantation in 8 cases), induced a significant increase of coronary TIMI flow grade (0.3 +/- 0.6 vs 2.4 +/- 0.9; p less than 0.05) and a significant decrease of thrombus score (size) 2.4 +/- 0.9 vs 1.3 +/- 0.6; p less than 0.01). No deaths nor need for urgent myocardial revascularization were observed; in 31% of cases (5 patients) evolution towards AMI occurred, while however 94% of cases (15 patients) had a coronary occlusion before treatment. No major hemorrhagic complications were observed, while in 12% of cases (2 patients) a groin hematoma associated with moderate hemoglobin drop, developed. In conclusion, the administration of abciximab, associated with the common rescue interventional procedures, in patients with acute thrombotic coronary occlusion in the Catheterization Laboratory, appears to be effective in restoring adequate coronary flow and reducing the thrombus size (limiting therefore the evolution towards AMI), and safe, not having been associated with significant hemorrhagic complications.
|
|
| 2. |
|
|
| 3. |
- Fransson, Sven-Göran, 1949-, et al.
(författare)
-
Immediate and late adverse reactions in coronary angiography. A comparison between iodixanol and ioxaglate
- 1996
-
Ingår i: Acta Radiologica. - : Informa Healthcare. - 0284-1851 .- 1600-0455. ; 37:2, s. 218-222
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose and Methods: In 120 patients in a double-blind, randomized, parallel study, iodixanol (Visipaque), a nonionic dimer isotonic with blood, was compared with ioxaglate (Hexabrix), an ionic low-osmolar dimer, in coronary angiography regarding early and late adverse reactions. Haemodynamic and electrophysiologic parameters were also analyzed. Results: Visipaque resulted in significantly fewer early adverse contrast medium related reactions (p less than 0.05). Visipaque also demonstrated significantly fewer effects on electrophysiologic parameters. Both contrast media reduced systolic and diastolic blood pressures at the Ist injection in the left coronary artery. Late adverse reactions were unusual with both contrast media and occurred only as urticaria with a frequency of 1.7%, which is lower than reported in i.v. studies. One serious adverse reaction, a myocardial infarction in a male patient with severe cardiovascular disease, occurred in the Visipaque group. This event was considered to be procedure- and disease-related rather than related to the type of contrast medium used. Conclusion: We found Visipaque safe for coronary angiography, causing fewer early adverse reactions than Hexabrix and also fewer effects on electrophysiologic parameters. Late adverse reactions seemed to be unusual with intra-arterial administration of contrast media.
|
|
| 4. |
- Fransson, Sven-Göran, 1949-
(författare)
-
Profiles in Cardiology: Olof Rudbeck : In Clinical Cardiology, Volume 20, Issue 11, pages 974–976
- 1997
-
Ingår i: Clinical Cardiology. - : John Wiley & Sons. - 0160-9289 .- 1932-8737.
-
Annan publikation (populärvet., debatt m.m.)abstract
- This Swedish man of science is best known for his discovery of the lymphatic system and for the dispute concerning priority over the Dane Thomas Bartholin who, in 1653, published his findings on the same subject just before Rudbeck. In Uppsala one year earlier, the 22-year-old Rudbeck, with his teacher, Professor Olaus Stenius, performed an anatomical demonstration of his results on a dog in the presence of Queen Christina of Sweden.
|
|
| 5. |
- Fransson, Sven Göran, 1949-
(författare)
-
The Botallo mystery
- 1999
-
Ingår i: Clinical Cardiology. - 0160-9289 .- 1932-8737. ; 22, s. 434-436
-
Tidskriftsartikel (refereegranskat)
|
|
| 6. |
- Fransson, Sven-Göran, 1949-
(författare)
-
Thoraxradiologisk historik
- 1995
-
Ingår i: Ett sekel med röntgenstrålar. - Linköping : Hälsouniversitet i Östergötland. - 9163035863
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 7. |
- Fransson, Sven-Göran, 1949-
(författare)
-
Urgammal behandlingsmetod. Åderlåtning mot gikt, feber, värk, epilepsi [Ancient therapeutic method. Bloodletting against gout, fever, pain, epilepsy]
- 1998
-
Ingår i: Läkartidningen. - 0023-7205 .- 1652-7518. ; 95:1-2, s. 74-76
-
Tidskriftsartikel (refereegranskat)abstract
- Den urgamla behandlingen åderlåtning intog en framträdande plats som medicinsk terapi i många kulturer under lång tid. Den användes mot i stort sett allt – feber, värk, epilepsi, melankoli, gikt, ödem, blödning samt inte minst vid dysenteri och i förlossningsvården. Trots viktiga medicinska upptäckter i Europa upphörde inte metoden förrän under senare hälften av 1800-talet. Vilka var då, i belysning av moderna rön, de medicinska effekterna av åderlåtning?
|
|
| 8. |
- Janerot-Sjöberg, Birgitta, et al.
(författare)
-
Femoral artery haemostasis with a pneumatic compression device versus a clamp after coronary angiography
- 1998
-
Ingår i: Scandinavian Cardiovascular Journal. - : Informa Healthcare. - 1401-7431 .- 1651-2006. ; 32:5, s. 281-284
-
Tidskriftsartikel (refereegranskat)abstract
- To evaluate the safety and efficacy of a new pneumatic compression device for achieving haemostasis after femoral artery catheterization, 1,017 patients undergoing selective coronary angiography by a SF unilateral femoral route were prospectively randomised to pneumatic or the routinely used clamp compression technique. All initial bleedings could be controlled in the pneumatic group, whereas in 38 patients (8%) of the clamp group the initial positioning of the clamp was unsuccessful or was not tolerated by the patient (p less than 0.05). Ultrasound Doppler study of the puncture site because of suspected postcatheterization vascular complication revealed two haematomas which needed no further measure and two pseudoaneurysms which were successfully treated with ultrasound-guided compression or surgical repair. The rate of complications requiring treatment (pseudoaneurysms) was 0.2% overall, 0.5% in the clamp group and nil in the pneumatic compression group (NS). We conclude that the pneumatic compression device is effective, convenient and at least as safe as the clamp and, by shortening the time in the catheterization laboratory, offers time for further angiograms.
|
|
| 9. |
- Jansson, K., et al.
(författare)
-
Mortality related to coronary angiography
- 1996
-
Ingår i: Clinical Radiology. - : Elsevier. - 0009-9260 .- 1365-229X. ; 51:12, s. 858-860
-
Tidskriftsartikel (refereegranskat)abstract
- Coronary angiography is in general regarded as a safe investigation with a low risk of serious complications, Unfortunately, a risk of serious complications exists, especially in patients with left main coronary artery disease or 3-vessel disease. The mortality rate ranges in different studies between 0.10% to 0.25%. The present series, reflecting nine gears experience, shows an overall mortality of 0.16%, This figure is influenced by the relatively high mortality: rate in the first year of the study, The recent mortality: rate of 0.07% has not changed in the last 3 years and almost all deaths occurred in the patients known to be at higher risk.
|
|
| 10. |
- Johansson, Torsten, et al.
(författare)
-
Intra- and Postoperative Cerebral Complications of Open-Heart Surgery
- 1995
-
Ingår i: Scandinavian Cardiovascular Journal. - : Informa Healthcare. - 1401-7431 .- 1651-2006. ; 29:1, s. 17-22
-
Tidskriftsartikel (refereegranskat)abstract
- A consecutive series of 1400 patients who had undergone open-heart surgery was retrospectively reviewed concerning postoperative cerebral dysfunction. The 30-day mortality was 1.6%. Forty-one patients (2.9%) showed signs of cerebral dysfunction, which proved fatal in seven cases. Neurologic symptoms were observed immediately after surgery in 14 patients, suggesting intraoperative damage. In 20 others there was an interval between surgery and the onset of cerebral symptoms, which in 12 cases were preceded by supraventricular tachycardia. Computed tomographic scans were performed on 27 patients and showed recent brain infarction in 22. No bleeding was found. At followup 34 of the 41 patients were alive, 21 of them with neurologic sequelae and 13 reporting complete recovery. Nineteen of the 34 survivors experienced no diminution of quality of life. Since half of the cerebral complications occurred postoperatively, more aggressive prevention and management of supraventricular tachyarrhythmia and anticoagulation therapy should be considered.
|
|
